SCHEMBL25296019

SCHEMBL25296019

COCCCc1ccc(OC)nc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
CYP2A6 P11509 1/20 0.40
KDM1A O60341 1/20 0.40
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
NNMT P40261 1/20 0.39
CYP11B1 P15538 1/20 0.38
DAO P14920 1/20 0.37
TUBB4A P04350 1/20 0.37
TUBB P07437 1/20 0.37
TUBA3C P0DPH7 1/20 0.37
TUBA1B P68363 1/20 0.37
TUBA4A P68366 1/20 0.37
TUBB4B P68371 1/20 0.37
TUBB3 Q13509 1/20 0.37
TUBB2A Q13885 1/20 0.37
TUBB8 Q3ZCM7 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13791527 0.84 CASP3 (0.53) CASP3SENP8SENP7SENP6KDM1A
SCHEMBL16797047 0.84 KDM4E (0.44) CASP3SENP8SENP7SENP6CYP2A6
SCHEMBL30381134 0.84 KDM4E (0.44) CASP3SENP8SENP7SENP6CYP2A6
SCHEMBL30380929 0.82 CYP4A11 (0.45) CASP3SENP8SENP7SENP6KDM1A
SCHEMBL6269874 0.82 CYP2A6 (0.44) CASP3SENP8SENP7SENP6CYP2A6
Ammonia Solution, Strong SCHEMBL6014377 0.82 CASP3 (0.51) CASP3SENP8SENP7SENP6KDM1A
SCHEMBL5756628 0.82 CYP4A11 (0.45) CASP3SENP8SENP7SENP6KDM1A
SCHEMBL16444063 0.82 CASP3 (0.41) CASP3SENP8SENP7SENP6CYP2A6
SCHEMBL20759038 0.82 CASP3 (0.59) CASP3SENP8SENP7SENP6KDM4E
SCHEMBL5759646 0.81 TAS2R14 (0.41) CASP3SENP8SENP7SENP6NNMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179032-A1 HETEROCYCLIC INHIBITORS OF GLUT9 FOR TREATMENT OF DISEASE HORIZON THERAPEUTICS IRELAND DAC (IE) 2025-06-05 US disclosed
CN-119013265-A GLUT9 heterocyclic inhibitors for the treatment of disease 爱尔兰好利恩治疗有限公司 2024-11-22 CN disclosed
EP-4460496-A1 HETEROCYCLIC INHIBITORS OF GLUT9 FOR TREATMENT OF DISEASE Horizon Therapeutics Ireland DAC (IE) 2024-11-13 EP disclosed
WO-2023131868-A1 HETEROCYCLIC INHIBITORS OF GLUT9 FOR TREATMENT OF DISEASE HORIZON THERAPEUTICS IRELAND DAC (IE) 2023-07-13 WO disclosed
WO-2023131868-A1 HETEROCYCLIC INHIBITORS OF GLUT9 FOR TREATMENT OF DISEASE HORIZON THERAPEUTICS IRELAND DAC (IE) 2023-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179032-A1 HETEROCYCLIC INHIBITORS OF GLUT9 FOR TREATMENT OF DISEASE SLC2A9, SLC2A1, SLC2A8 CASP3 1399/4885SENP8 1612/4885SENP7 2416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.